This document provides the strategic direction regarding tackling fraud, bribery, corruption and economic crime.
Guidance on Better Care Fund planning requirements, which support the core NHS operational planning and contracting guidance for 2019 to 2020 that also details the Better Care Fund operating guidance.
A letter to suppliers giving an update on ensuring a continued supply of medicines and medical products if the UK leaves the EU with no deal. The letter sets out: how the government plans to ensure a continued supply of
Report that explores the feasibility of introducing one type of flexible payment mechanism –outcome-based payment (OBP) –for cancer medicines into the NHS in England. This model links the price the NHS pays for a medicine to the outcomes it achieves
Information for NHS providers about the extensive planning and contingency measures that have been put in place for the healthcare system nationally and the additional actions that we are asking providers to undertake as a priority as part of the
This document sets out the national approach to managing contractual disputes between NHS commissioners and Trusts under the 2018/19 Year To Date Contract Alignment Exercise.
The voluntary scheme for branded medicines pricing and access is a non-contractual voluntary agreement between the Department of Health and Social Care (DHSC) and the Association of the British Pharmaceutical Industry (ABPI). DHSC is acting on behalf of the UK government,
During 2017, the prices of certain generic medicines purchased by community pharmacies for the NHS increased unexpectedly, affecting an unusually high number of medicines. Although the Department of Health & Social Care (the Department) and its arms-length bodies took action
The NHS terms and conditions are for the use of NHS bodies procuring goods and services from commercial organisations. They were updated in January 2018 to reflect changes in government policy and General Data Protection Regulation (GDPR) legislation.
Proposes new approaches in three areas to improve understanding of supply side opportunity costs for the NHS. It explores improving efficiency, production functions and purchaser priorities.
Report from the House of Commons Public Accounts Committee that find NHS England’s outsourcing of primary care support services to Capita Business Services Ltd (Capita) a shambles. Its short-sighted rush to slash by a third the £90 million it cost
Report from the National Audit Office that finds an increase in prices of certain generic medicines: The NHS spent an estimated £4.3 billion on generic medicines in 2016‑17, of which most was spent in primary care. The prices of certain generic
This report from the Carter review has looked at the productivity and efficiency of mental health and community health services. It has done so in the context of the Five Year Forward View and its delivery plan which are clear that these
Report from the King’s Fund that looks at how much the health service spends in total on medicines, both generics and branded medicines, based on publicly available data. In recent years, spending on branded medicines has been constrained by the Pharmaceutical
NHS efficiency map case study from the HFMA, identifies that the price of fuel amounts to a significant non-pay cost for ambulance trusts. East Midlands Ambulance Service NHS Trust provides a case study in using bunkered fuel that the trust has purchased at a reduced
The purpose of this paper is to give an overview of the current arrangements for the procurement of medicines and pharmaceutical products and services in the UK. It includes an overview of arrangements for NHS England, NHS Scotland, NHS Wales and HSC Northern
This case study covers the use of scanning (of products, places and patients) to improve efficiency and safety. It initially arose from a procurement strategy, but has now gone wider than that, addressing the wider NHS issue of having information readily available to make the right decisions.
Outlines the level of payment due from members of the Pharmaceutical Price Regulation Scheme (PPRS) in 2018. This will be 7.80%. The PPRS is a voluntary agreement to control the prices of branded drugs sold to the NHS. It is negotiated between the Department of
Nuffield Trust report on the slow adoption of innovations by the NHS that finds it is due to: An overly supply-driven and top-down approach to innovation. Shifts towards the co-production of solutions between clinicians and industry are encouraging, but initiatives